Ajanta Pharma Limited has successfully completed its share dematerialization confirmation for the quarter ended 31st March 2026. Through its Registrar and Share Transfer Agent, MUFG Intime India Private Limited, the company verified that all securities received from depository participants during the period were processed, mutilated, and cancelled in accordance with established timelines. This ensures that the company’s register of members accurately reflects the updated shareholding status.
Quarterly Dematerialization Update
Ajanta Pharma has confirmed the completion of its mandatory share processing tasks for the fourth quarter (January to March 2026) of the current financial year. The process, managed by the company’s registrar, confirms that all physical securities submitted for dematerialization were duly verified and processed within the required regulatory window.
Process Integrity and Verification
As part of the routine reconciliation process, all security certificates received during this period were physically mutilated and cancelled following rigorous verification. The company has ensured that the depository records and the internal register of members have been updated to reflect these changes accurately. This verification ensures full transparency for shareholders and confirms that the relevant securities have been appropriately listed on the stock exchanges.
Next Steps for Shareholders
With this confirmation, the company continues to maintain its standard operational efficiency in managing equity records. Shareholders are encouraged to note that all requests submitted within the Q4 FY26 timeframe have been successfully processed, ensuring their holdings are seamlessly integrated into the electronic depository system.
Source: BSE
